Revolutionizing vector engineering by leveraging a billion years of natures wisdom.
At rAAVen, our mission is to create gene-therapy delivery vectors that benefit people with serious and potentially fatal health conditions. We work closely with biotech and pharmaceutical companies to provide patients with the best possible treatment option.
Founded in 2022 by COO Marcus Davidsson, PhD, rAAVen Therapeutics set out with the clear goal of offering superior selectivity and efficiency over existing AAV technologies, as well as creating AAV capsids suitable for unique applications. To reach these goals, rAAVen set out and successfully created an easy to use, scalable platform, focusing on rational design for identifying viral capsids from large pools of viral variants with desirable traits. rAAVen chose to focus on capsid insertion of rationally designed peptides inspired by nature, as we believe that evolution has already created highly efficient protein-protein interactors that can be leveraged for viral entry.
With greater expansion of highly efficient AAV vectors, tailor made for specified tissues or cell types, future gene therapy is not limited by the biology of the wild-type AAV capsids, or to rare disorders.
rAAVen Theraputics story began when the scientific team established a working screening platform based on DNA barcoding for identifying desirable AAV capsids from large pools. We first utilized our platform in the CNS, were we successfully created AAV capsids capable of synaptic infectivity and retrograde transport within the CNS of a rat. This was achieved through a single round of selection and proved to be translatable to human grafted neurons within the rat CNS. We were also able to create novel capsids with high efficacy for human astrocytes as well as human dopaminergic neurons.
We now offer our unique platform for use in screening for rationally designed AAV capsids targeted for specific tissues and cell types, as well as screenings of promotor/enhancer elements for even stronger selected expression, improving both efficacy and safety for future clinical trials. Our screens are offered across model systems in multiple simultaneous organ and cell types ranging from rodents, to non-human primates and through any desired viral delivery method.
rAAVen Therapeutics has in short order developed a state-of-the-art fully functioning, high throughput platform for screening AAV capsids with substantial expertise in vector engineering.
We are happy to partner with likeminded folks. Don’t hesitate to contact us to help you fulfill your capsid engineering needs.
Sincerely,
The rAAven team
Are you dedicated to develop revolutionary gene therapies for patients? We would love to hear from you.
species proteomes evaluated for insertion
designed libraries
AAV wild-type capsids modified
rAAVen Therapeutics is a CRO (Contract Research Organization) company that specializes in the development and engineering of modified AAV (adeno-associated virus) for customers who are developing gene therapies. rAAven’s capsids are highly efficient at delivering therapeutic genes to target cells.
AAV capsids are the protective shells of AAVs that interact with the cell membrane in order to deliver therapeutic genes to target cells in gene therapy. AAV capsid modifications involve the design of AAV capsids that are optimized for targeting specific cell populations.
rAAVen Therapeutics specializes in a rational design approach to modify AAV capsids to improve their performance for gene therapy applications.
Our technology allows us to create novel AAV capsids that are highly efficient at delivering therapeutic genes to target cells. Our experienced team of scientists and state-of-the-art facility enables us to rapidly design and produce AAV capsids that are tailored to meet the specific needs of each project. This means that our customers can rely on us for the most advanced AAV capsids available on the market.
Our modified AAV capsids can be used for a wide range of gene therapy applications, including but not limited to: inherited genetic disorders, cancer, and gene editing.
Our AAV capsids have been used to successfully target specific cell types and for novel applications. We are proud to partner with some of the most innovative biotech and pharmaceutical companies in the industry to advance the field of gene therapy and bring new treatments to patients in need.
Our team is dedicated to providing our customers with the highest level of support throughout their AAV gene therapy development process. We are committed to working closely with our customers to understand their specific needs and develop a customized approach to meet those needs.
We would be happy to provide you with more information about our company and services. Please contact us to speak with one of our representatives for more information.
Contact Us
Feeling called to revolutionize the gene therapy industry? We are happy to hear from you.
